Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Entera Bio Ltd., a clinical-stage biotechnology company developing oral peptide therapeutics, announced a private placement led by BVF Partners that raises $10 million in gross proceeds, with warrants that could bring total proceeds to $24.5 million. The funding will support the initiation of a phase 3 study of its lead product candidate EB613 for …